Default company panoramic image

SEKRIS Biomedical, Inc.

SEKRIS Biomedical, Inc. is a privately held company that was founded in 2009 by Dr. Alan Escher and Dr. Shahrokh Shabahang. In 2011, SEKRIS signed an exclusi...

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Redlands, CA, USA
  • Currency USD
  • Founded May 2009
  • Employees 4
  • Website

Company Summary

SEKRIS Biomedical, Inc. is a privately held company that was founded in 2009 by Dr. Alan Escher and Dr. Shahrokh Shabahang. In 2011, SEKRIS signed an exclusive worldwide license for the rights to the entire patent portfolio and technology to further develop it for clinical trials. This platform has wide applications to many diseases including diabetes, organ transplant rejection, autoimmune diseases, asthma and allergies.


  • Default avatar
    Shahrokh Shabahang

    Dr. Shabahang is a co-founder and President of SEKRIS Biomedical, Inc. He received his DDS in 1987 from University of Pacific, specialty training and MS in 1997 from Loma Linda University, and a PhD in Microbiology and Molecular Genetics from Loma Linda University in 2001. During his tenure as a member of the faculty at Loma Linda University, he maintained a laboratory with research emphasis on the effects of local infections on systemic diseases

  • Default avatar
    Alan Pierre Escher
    EVP of Technology Development

    Dr. Alan Escher received his BSc magna cum laude from the University of Connecticut and PhD from Cornell University. Dr. Escher is co-founder of SEKRIS and heading its R&D program. He was previously Associate Professor and Associate Director of the Center for Transplant Immunology Research at the Loma Linda University School of Medicine, where Dr. Escher and colleagues started to develop pro-apoptotic DNA vaccination for the treatment of type 1 d

  • Default avatar
    Joachim-Friedrich Kapp
    Medical Director

    Dr. Joachim-Friedrich Kapp joined Schering AG, Germany, in 1975 as a scientist in the Department of Inflammation Research and Immunology. He became Section Head in 1976 and Department Head in 1977. In 1980 he transferred as Medical Director to Schering’s newly acquired US subsidiary, Berlex, and was appointed Vice President and Head of Research and Development in 1981. From 1984 through 1990 he was with Warner-Lambert’s German subsidiary Goedecke

  • Default avatar
    Neil Desai
    Technology Advisor

    Dr. Neil P. Desai PhD serves as Vice President, Strategic Platforms at Celgene Corp. Dr. Desai has more than 20 years of experience in the research and development of novel therapeutics, drug delivery systems and biocompatible polymers. Until October 2010, he served as Senior Vice President, Global Research and Development at Abraxis BioScience, Inc. (ABI) where he was responsible for the development of ABI's proprietary product pipeline and inte

  • Default avatar
    Charles Crocker
    Finance Advisor

    Charles Crocker is Chairman and CEO of Crocker Capital, a private venture capital firm. Mr. Crocker served as Chairman of the Board and CEO of BEI Technologies, Inc., a NASDAQ listed, diversified technology company, which he founded. BEI was sold to Schneider Electric, a global French conglomerate, in October, 2005. Mr. Crocker was also Chairman, CEO, and founder of BEI Medical Systems, a public medical device company, sold to Boston Scientifi


  • Default avatar
    Jan Sundberg, JD, Corporate Counsel; James Hill, MD, JD, IP Counsel
    Default avatar
    Kelly Allen, CPA, CVA, CFF

Previous Investors

  • Default avatar
    Management Team